News | January 20, 1999

IRIDEX Announces Shipment of New Visible Green Light Portable Laser Photocoagulator

MOUNTAIN VIEW, CALIF. (Jan. 20) BUSINESS WIRE- Jan. 20, 1999--IRIDEX Corporation (Nasdaq/NMS:IRIX) announced today it started shipping the new IRIS Medical OcuLight(R) GLx semiconductor-based green laser photocoagulator.

This laser further expands the market opportunities of the OcuLight product family by increasing the clinical and delivery device versatility currently available to ophthalmologists.

The OcuLight GLx has increased power and delivery device capability compared to the OcuLight GL laser. The OcuLight GLx can adapt to a completely integrated Laser/Slit Lamp Workstation providing uncompromised diagnostic and treatment capabilities.

The workstation provides a laser delivery device with a 50-1000 micron zoom spot size, electronically actuated eye safety filter and a micromanipulator for precise targeting. The OcuLight GLx also attaches to IRIS Medical's complete line of visible delivery devices including portable UltraView(tm) Slit Lamp Adapters, TruFocus(tm) Laser Indirect Ophthalmoscope and EndoProbe(R) devices.

The OcuLight GL product was the first continuous wave (CW) completely solid-state visible laser photocoagulator used by ophthalmologists to treat a variety of retinal and glaucoma eye diseases. While able to perform all the same clinical applications as traditional argon gas-tube lasers, at 12" x 12" x 6", it is only a fraction of the size and weighs only 15 pounds.

The new OcuLight GLx incorporates the Company's patented technology that improves laser efficiency and reliability, eliminates alignment sensitivity and the need for water cooling, and allows the OcuLight GLx to turn on instantly and produce TrueCW(tm) green laser light. Its solid-state design eliminates all laser tubes and arc lamps as well as their associated high voltages, maintenance and service requirements.

"We believe the new OcuLight GLx is an exceptional value to the ophthalmologist who prefers green laser light. It offers the versatility of multiple delivery devices with the convenience of portability," commented Theodore A. Boutacoff, President and Chief Executive Officer. "We also believe this product will successfully meet the increasing demand for photocoagulators that are portable and durable enough to be carried between offices and can be used in an office or hospital setting."

IRIDEX Corporation is the leading worldwide provider of semiconductor-based laser systems used to treat eye disease for ophthalmology and skin lesions for dermatology. IRIDEX products are sold in the United States predominantly through a direct sales force and internationally through 53 independent distributors into 71 countries. The Company markets its products using three brand names: IRIS Medical to the ophthalmic market, IRIDERM to the dermatological market, and Light Solutions to the research market.

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. Actual results could differ materially from those projected in the forward-looking statements due to risks associated with dependence on international sales, competition, quarterly fluctuations in operating results, as well as risks associated with dependence on development of new products and new applications. For additional risks and uncertainties, the Company incorporates by reference the risks set forth in the Company's 1997 Form 10-K which was filed on March 31, 1998, and Form 10-Q which was filed on November 16, 1998, including Continued Market Acceptance of the Company's Products, Risks of Manufacturing and Dependence on Key Manufacturers and Suppliers, Dependence on Collaborative Relationships, Patents and Proprietary Rights, Government Regulation, and such other risks detailed from time to time in the Company's reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.


Robert Kamenski, 650/940-4700

On The Net- Business Wire's full file on the Internet

with Hyperlinks to your home page.